Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Durrington

Showing results (1-10 of 43) with videos related to

Pageof 5
Sort By:
The Lancet. Diabetes & Endocrinology|January 9, 2023
Blood lipids after COVID-19 infectionPaul Durrington
Lancet (London, England)|September 6, 2003
DyslipidaemiaPaul Durrington
Current Opinion in Lipidology|July 10, 2004
Statin policy and target populations: evidence-based or evidence-biased?Paul Durrington
Nature Clinical Practice. Cardiovascular Medicine|October 26, 2006
Does statin therapy improve short-term clinical outcomes in acute coronary syndromes?Paul Durrington
Atherosclerosis. Supplements|February 8, 2003
HDL in risk prediction and its direct and indirect involvement in atherogenesisPaul Durrington
Journal of the Royal Society of Medicine|May 4, 2004
Clinical management of children and young adults with heterozygous familial hypercholesterolaemia in the UKOwen Greene, Paul Durrington
Current Opinion in Lipidology|June 18, 2024
Paraoxonase 1: evolution of the enzyme and of its role in protecting against atherosclerosisPaul Durrington, Handrean Soran
Expert Opinion on Pharmacotherapy|August 2, 2008
Rosuvastatin: efficacy, safety and clinical effectivenessHandrean Soran, Paul Durrington
Current Opinion in Lipidology|July 10, 2004
Paraoxonase 1 activity, concentration and genotype in cardiovascular diseaseMike Mackness, Paul Durrington, Bharti Mackness
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|January 27, 2017
Evidence-based goals in LDL-C reductionHandrean Soran, Ricardo Dent, Paul Durrington
Pageof 5

Showing results (1-10 of 43) with videos related to

Sort By:
Pageof 5
The Lancet. Diabetes & Endocrinology|January 9, 2023
Blood lipids after COVID-19 infectionPaul Durrington
Lancet (London, England)|September 6, 2003
DyslipidaemiaPaul Durrington
Current Opinion in Lipidology|July 10, 2004
Statin policy and target populations: evidence-based or evidence-biased?Paul Durrington
Nature Clinical Practice. Cardiovascular Medicine|October 26, 2006
Does statin therapy improve short-term clinical outcomes in acute coronary syndromes?Paul Durrington
Atherosclerosis. Supplements|February 8, 2003
HDL in risk prediction and its direct and indirect involvement in atherogenesisPaul Durrington
Journal of the Royal Society of Medicine|May 4, 2004
Clinical management of children and young adults with heterozygous familial hypercholesterolaemia in the UKOwen Greene, Paul Durrington
Current Opinion in Lipidology|June 18, 2024
Paraoxonase 1: evolution of the enzyme and of its role in protecting against atherosclerosisPaul Durrington, Handrean Soran
Expert Opinion on Pharmacotherapy|August 2, 2008
Rosuvastatin: efficacy, safety and clinical effectivenessHandrean Soran, Paul Durrington
Current Opinion in Lipidology|July 10, 2004
Paraoxonase 1 activity, concentration and genotype in cardiovascular diseaseMike Mackness, Paul Durrington, Bharti Mackness
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|January 27, 2017
Evidence-based goals in LDL-C reductionHandrean Soran, Ricardo Dent, Paul Durrington
Pageof 5